Whether it’s Snake’s elevator ascent to the rainy cliffs of Shadow Moses or the climactic battle between student and mentor ...

Apparently, a bunch of "primitivist" poor people got together to pull off a "Great Reset" in the shape of a worldwide nuclear ...

Long-time Atlus composer Shoji Meguro is leading his own game that's getting a demo very soon, and it's basically a cross between Persona and Metal Gear Solid.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. The biotech reported expectation-busting phase 1 data on its next-generation candidate, sending its ...

Solid Biosciences said Tuesday that the first three patients to receive its experimental gene therapy for Duchenne muscular dystrophy all produced high levels of microdystrophin, a miniature ...

An experimental Duchenne muscular dystrophy gene therapy from Solid Biosciences showed potential in a small clinical trial, leading the biotechnology company to quickly raise funds on the findings.

Solid Biosciences’ gene therapy candidate for patients with Duchenne muscular dystrophy (DMD) has elicited a 110% expression of the microdystrophin gene. The US-based company’s stock soared by ...

Also Read: Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development The company also reported lower markers of muscle injury and stress, along with an 8% average improvement in ...

Solid Biosciences Inc. (NASDAQ:SLDB), a clinical-stage biotechnology company specializing in gene therapies for muscle and cardiac diseases, stands at a critical juncture as it approaches key ...

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne ...